ORIENTBIO Inc. (002630) - Total Liabilities
Based on the latest financial reports, ORIENTBIO Inc. (002630) has total liabilities worth ₩12.64 Billion KRW (≈ $8.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ORIENTBIO Inc. - Total Liabilities Trend (2006–2025)
This chart illustrates how ORIENTBIO Inc.'s total liabilities have evolved over time, based on quarterly financial data. See ORIENTBIO Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
ORIENTBIO Inc. Competitors by Total Liabilities
The table below lists competitors of ORIENTBIO Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eureka Acquisition Corp Unit
NASDAQ:EURKU
|
USA | $1.53 Million |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
USA | $53.74 Million |
|
Suprema HQ Inc
KQ:094840
|
Korea | ₩7.40 Billion |
|
Evermore Chemical Industry Co Ltd
TW:1735
|
Taiwan | NT$1.40 Billion |
|
E & M Computing Ltd
TA:EMCO
|
Israel | ILA666.51 Million |
|
Menderes Tekstil Sanayi ve Ticaret AS
IS:MNDRS
|
Turkey | TL7.21 Billion |
|
Metrofile
JSE:MFL
|
South Africa | ZAC895.00 Million |
|
Company K Partners Limited
KQ:307930
|
Korea | ₩8.74 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down ORIENTBIO Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORIENTBIO Inc. (002630) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORIENTBIO Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORIENTBIO Inc. (2006–2025)
The table below shows the annual total liabilities of ORIENTBIO Inc. from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₩12.94 Billion ≈ $8.77 Million |
+8.77% |
| 2024-03-31 | ₩11.89 Billion ≈ $8.06 Million |
+23.13% |
| 2023-03-31 | ₩9.66 Billion ≈ $6.54 Million |
-55.63% |
| 2022-03-31 | ₩21.76 Billion ≈ $14.75 Million |
-5.26% |
| 2021-03-31 | ₩22.97 Billion ≈ $15.57 Million |
+14.05% |
| 2020-03-31 | ₩20.14 Billion ≈ $13.65 Million |
-6.06% |
| 2019-03-31 | ₩21.44 Billion ≈ $14.53 Million |
-80.53% |
| 2018-03-31 | ₩110.11 Billion ≈ $74.62 Million |
+47.44% |
| 2017-03-31 | ₩74.68 Billion ≈ $50.61 Million |
-11.47% |
| 2016-03-31 | ₩84.35 Billion ≈ $57.16 Million |
+3.61% |
| 2015-03-31 | ₩81.42 Billion ≈ $55.17 Million |
+4.67% |
| 2014-03-31 | ₩77.78 Billion ≈ $52.71 Million |
+5.18% |
| 2013-03-31 | ₩73.95 Billion ≈ $50.12 Million |
+17.33% |
| 2012-03-31 | ₩63.03 Billion ≈ $42.72 Million |
+225.32% |
| 2011-03-31 | ₩19.38 Billion ≈ $13.13 Million |
-54.46% |
| 2010-03-31 | ₩42.55 Billion ≈ $28.83 Million |
+4.85% |
| 2009-03-31 | ₩40.58 Billion ≈ $27.50 Million |
-9.68% |
| 2008-03-31 | ₩44.93 Billion ≈ $30.45 Million |
+60.37% |
| 2007-03-31 | ₩28.02 Billion ≈ $18.99 Million |
+16.95% |
| 2006-03-31 | ₩23.96 Billion ≈ $16.24 Million |
-- |
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more